Equillium (EQ) Cash from Financing Activities (2018 - 2026)
Equillium's (EQ) quarterly Cash from Financing Activities came in at $35.3 million in Q1 2026, up 38741.76% year-on-year from N/an in Q1 2025, and up 12389.75% on a QoQ basis from $283000.0 in Q4 2025.
Equillium (EQ) Cash from Financing Activities (2018 - 2026) Analysis & Trends
Equillium (EQ) has 9 years of Cash from Financing Activities data on file, last reported at $35.3 million in Q1 2026.
- On a quarterly basis, Cash from Financing Activities rose 38741.76% year-over-year to $35.3 million in Q1 2026; TTM through Mar 2026 was $65.7 million, a 26929.63% increase from a year earlier, with the FY2025 full-year figure at $30.4 million, up 18453.05% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $35.3 million, up from $283000.0 in the prior quarter.
- Over the last five years, Cash from Financing Activities for EQ reached as high as $35.3 million in Q1 2026 and fell as low as -$7.6 million in Q2 2023.
- Historically, Cash from Financing Activities has averaged $5.0 million across 5 years, with a median of $73000.0 in 2024.
- Across the five-year window, Cash from Financing Activities tumbled 702.67% in 2022 and surged 38741.76% in 2026, its largest moves.
- Year by year, Cash from Financing Activities stood at -$1.4 million in 2022, then soared by 105.83% to $79000.0 in 2023, then retreated by 7.59% to $73000.0 in 2024, then jumped by 287.67% to $283000.0 in 2025, then surged by 12389.75% to $35.3 million in 2026.
- Per Business Quant data, the three most recent Cash from Financing Activities figures were $35.3 million in Q1 2026, $283000.0 in Q4 2025, and $30.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Equillium | 258.99 Mn | 258.99 Mn | - | 35.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 35.35 Mn |
| Mar 31, 2026 | 35.35 Mn |
| Dec 31, 2025 | 283,000.00 |
| Dec 31, 2025 | 283,000.00 |
| Sep 30, 2025 | 30.07 Mn |
| Sep 30, 2025 | 30.07 Mn |
| Jun 30, 2025 | -16,000.00 |
| Jun 30, 2025 | -16,000.00 |
| Mar 31, 2025 | 91,000.00 |
| Mar 31, 2025 | 91,000.00 |
| Dec 31, 2024 | 73,000.00 |
| Dec 31, 2024 | 73,000.00 |
| Dec 31, 2023 | 79,000.00 |
| Dec 31, 2023 | 79,000.00 |
| Sep 30, 2023 | -260,000.00 |
| Sep 30, 2023 | -260,000.00 |
| Jun 30, 2023 | -7.62 Mn |
| Jun 30, 2023 | -7.62 Mn |
| Mar 31, 2023 | -1.43 Mn |
| Mar 31, 2023 | -1.43 Mn |